Novo Nordisk Has Announced That The European Commission Has Granted An Extension Of The Indication For Its Fast-Acting Insulin Aspart, Fiasp.The Extension Is For The Treatment Of Diabetes In Adolescents And Children (Aged One Year And Above), Complementing The Previous Indication, Which Covered Adults Only.
